Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26860530 | 0.85 | ADORA2B (0.30) | ADORA2B | |
| SCHEMBL16339754 | 0.82 | ADORA2B (0.31) | ADORA2BADORA2APTGS1L3MBTL1 | |
| SCHEMBL2678381 | 0.81 | USP2 (0.33) | ALDH1A1ADORA2BGAAHRH4 | |
| SCHEMBL11469821 | 0.74 | NOS3 (0.38) | NOS3NOS1NOS2HRH3ALDH1A1 | |
| SCHEMBL4279839 | 0.74 | IRAK4 (0.30) | — | |
| SCHEMBL2737328 | 0.73 | ALDH1A1 (0.35) | NOS3NOS1NOS2ALDH1A1GAA | |
| SCHEMBL2610824 | 0.73 | BAZ2B (0.39) | NOS3NOS1NOS2ALDH1A1ADORA2B | |
| SCHEMBL6229727 | 0.73 | ADORA2B (0.33) | ADORA2BGAA | |
| SCHEMBL17045358 | 0.73 | ADORA2A (0.39) | NOS3NOS1NOS2HRH3ALDH1A1 | |
| SCHEMBL19992372 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018021-B2 | Thiophene derivatives for the treatment of disorders caused by IgE | UCB Biopharma SRL (BE) | 2024-06-25 | — | — | US | disclosed |
| EP-3908579-B1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | JANSSEN BIOTECH INC (US) | 2023-12-27 | — | — | EP | disclosed |
| WO-2023216237-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS, AND METHODS OF USE THEREOF | JS INNOMED HOLDINGS LTD. (KY) | 2023-11-16 | — | — | WO | disclosed |
| US-20230286973-A1 | PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2023-09-14 | — | — | US | disclosed |
| US-20230286973-A1 | PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2023-09-14 | — | — | US | disclosed |
| US-20220332709-A1 | Thiophene derivatives for the treatment of disorders caused by IgE | UCB Biopharma SRL (BE) | 2022-10-20 | — | — | US | disclosed |
| US-11312722-B2 | Hsp90 inhibitors and uses thereof | TRUSTEES OF BOSTON UNIVERSITY (US) | 2022-04-26 | — | — | US | disclosed |
| US-20220089568-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | JANSSEN BIOTECH, INC. | 2022-03-24 | — | — | US | disclosed |
| CN-110049977-B | Lactam, cyclic urea and carbamate and triazolone derivatives as potent and selective ROCK inhibitors | 百时美施贵宝公司 | 2022-01-18 | — | — | CN | disclosed |
| EP-3908579-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | Janssen Biotech, Inc. (US) | 2021-11-17 | — | — | EP | disclosed |
| WO-2005060970-A1 | PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2005-07-07 | — | — | WO | disclosed |
| EP-0114273-B1 | NEW PHARMACOLOGICALLY ACTIVE PYRAZOLOPYRIDINES | GRUPPO LEPETIT S.p.A. (IT) | 1991-11-06 | — | — | EP | disclosed |
| US-4954508-A | HYPOTENSIVE | GRUPPO LEPETIT S.P.A. (IT) | 1990-09-04 | — | — | US | disclosed |
| US-4873334-A | HYPOTENSIVE AGENTS, CORONARY VASODILATORS | SHIONOGI & CO., LTD. (JP) | 1989-10-10 | — | — | US | disclosed |
| EP-0107619-B1 | DIHYDROPYRAZOLO(3,4-B)PYRIDINE DERIVATIVES AND PRODUCTION THEREOF | SHIONOGI & CO., LTD. (JP) | 1987-07-29 | — | — | EP | disclosed |
| EP-0114273-A1 | New pharmacologically active pyrazolopyridines | GRUPPO LEPETIT S.p.A. (IT) | 1984-08-01 | — | — | EP | disclosed |
| EP-0107619-A1 | Dihydropyrazolo(3,4-b)pyridine derivatives and production thereof | SHIONOGI & CO., LTD. (JP) | 1984-05-02 | — | — | EP | disclosed |
| US-4234594-A | Pyrazolyl amino imidazolines as antihypertensive agents | ABBOTT LABORATORIES (US) | 1980-11-18 | — | — | US | disclosed |
| US-4226773-A | Pyrazolyl amino imidazolines as diuretic agents | ABBOTT LABORATORIES (US) | 1980-10-07 | — | — | US | disclosed |
| US-4171367-A | ANTIINFLAMMATORY | ABBOTT LABORATORIES (US) | 1979-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089568-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | DHODH, DLD, DPYD | NOS3 1205/4885NOS1 1007/4885NOS2 1336/4885 |
| US-20220332709-A1 | Thiophene derivatives for the treatment of disorders caused by IgE | TSLP, CYSLTR1, CYSLTR2 | NOS3 1677/4885NOS1 651/4885NOS2 1492/4885 |
| US-20230286973-A1 | PROTEIN SECRETION INHIBITORS | SEC61B, SEC61A1, SEC61G | NOS3 4218/4885NOS1 3305/4885NOS2 4142/4885 |
| US-12018021-B2 | Thiophene derivatives for the treatment of disorders caused by IgE | TSLP, CYSLTR1, CYSLTR2 | NOS3 1677/4885NOS1 651/4885NOS2 1492/4885 |
| US-11312722-B2 | Hsp90 inhibitors and uses thereof | HSP90AB1, HSP90B1, HSP90AA1 | NOS3 894/4885NOS1 901/4885NOS2 918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.